A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

NCT06412471 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

First-line Advanced NSCLC Patients

Interventions

DRUG: SSGJ-707
DRUG: carboplatin
DRUG: Pemetrexed
DRUG: paclitaxel
DRUG: PD-1/L1
DRUG: Paclitaxel-albumin

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.